A real-world study linked mepolizumab therapy with fewer healthcare visits and symptom improvements in patients with chronic rhinosinusitis with nasal polyps. The dataset adds to the evidence base for anti–IL-5 pathway approaches beyond controlled trials by capturing how outcomes trend in routine care. For ENT and immunology stakeholders, the practical signal—reduced utilization paired with symptom benefit—can inform payer conversations and clinical positioning for biologics in nasal polyp populations, especially where disease burden drives repeat care and escalation.